COVID-19: Roche’s antibody cocktail launch in India at 59 Rupees
By Sanjay Maurya
News Highlights
- Roche India and Cipla announced the launch of Roche’s Antibody Cocktail in India on 24th May, priced at INR 59,750 per dose.
- In India, the first batch of the Antibody Cocktail is now available, with a second batch expected by mid-June.
- They can help 2,00,000 patients because each of the 1,00,000 packs available in India treats two patients.
Roche’s antibody cocktail for Covid-19 treatment launch in India at 59 Rupees
Roche India and Cipla announced the launch of Roche’s Antibody Cocktail in India on 24th May, priced at INR 59,750 per dose, for the treatment of mild to moderate COVID-19 in high-risk patients. In India, the first batch of the Antibody Cocktail is now available, with a second batch expected by mid-June.
They can help 2,00,000 patients because each of the 1,00,000 packs available in India treats two patients,” Cipla and Roche said in a joint statement. Cipla will sell the Roche Antibody Cocktail around the country by exploiting its broad logistics capabilities,” it said.
Adults and pediatric patients (12 years of age or older, weighing at least 40 kg) who are infected with SARS-COV2 who are at high risk of developing serious COVID-19 disease and do not need oxygen will be given the antibody cocktail to treat mild to moderate coronavirus disease.
According to the firm, the cocktail has been shown to benefit these high-risk patients before their illness worsens, reducing the risk of hospitalization and death by 70%. According to Roche India, the antibody combination can help 200,000 patients since each of the 100,000 packs available in India would treat two patients.
How to Buy Roche’s antibody cocktail?
Casirivimab and Imdevimab, an antibody cocktail drug, will be available through Cipla’s distribution network across the world. Private and public healthcare agencies will inquire by contacting their local Cipla distributor.
Cipla, an Indian pharmaceutical company, will sell the medication. Leading clinics and COVID treatment centers would be eligible to obtain the medication. The Antibody Cocktail (Casirivimab and Imdevimab) recently received an Emergency Use Authorization (EUA) from the Central Drugs Standards Control Organization (CDSCO) in India. It has also been granted EUA in the United States and other European countries.
Covid-19 Cases update
According to data updated on 24th May by the Union Health Ministry, India reported 2,22,315 new coronavirus infections in a single day, the lowest in nearly 38 days, bringing the overall number of COVID-19 cases to 2,67,52,447 and the death toll to over 3 lakhs. With 4,454 deaths per day, the death rate has risen to 3,03,720.
